| Vaccitech–Minapharm: cell line, 201905– license to ProBioGen’s AGE1.CR duck cell line for production of viral vectored vaccines |
2019-05-15 |
| Icometrix–Bertarelli Group: investment, 201905 financing round totalling $18m incl new + lead investor Forestay Capital |
2019-05-14 |
| Icometrix–Capricorn Venture Partners: investment, 201905 financing round totalling $18m incl existing + co-investor Capricorn Venture Partners |
2019-05-14 |
| Icometrix–SEVERAL: investment, 201905 financing round $18m led by Forestay Capital + incl Optum Ventures + Capricorn Venture Partners |
2019-05-14 |
| Icometrix–UnitedHealth: investment, 201905 financing round totalling $18m incl new + co-investor Optum Ventures |
2019-05-14 |
| Philogen–Consilium: public relations, 201905 service existent by CSC |
2019-05-13 |
| Philogen–SEVERAL: investment, 201905 financing round €62m from existing + new private investors |
2019-05-13 |
| TreeFrog Therapeutics–SEVERAL: investment, 201905 financing round Series A €6.5m led by XAnge + incl Galia Geston et al |
2019-05-13 |
| Priavoid–PERSON: investment, 201905c Detlev Riesner recently acquired shares of Priavoid GmbH |
2019-05-10 |
| MabVax Therapeutics–BioNTech: investment, 201905 acquisition €na of antibody assets + infrastructure + lab equipment in San Diego |
2019-05-08 |
| Therachon–Cowen: investment, 201905 existing investor Cowen |
2019-05-08 |
| Therachon–France (govt): investment, 201905 existing investors Bpifrance + Inserm Transfert Initiative |
2019-05-08 |
| Therachon–Novo Group: investment, 201905 existing investor Novo Holdings |
2019-05-08 |
| Therachon–OrbiMed: investment, 201905 existing investor OrbiMed |
2019-05-08 |
| Therachon–Pfizer: investment, 201905 existing investor Pfizer Ventures |
2019-05-08 |
| Therachon–Pfizer: investment, 201905– acquisition 100% $340m upfront + $470m milestones excl apraglutide development program |
2019-05-08 |
| Therachon–Tekla Capital: investment, 201905 existing investor Tekla Capital Management LLC |
2019-05-08 |
| Therachon–Versant Ventures: investment, 201905 existing investor Versant Ventures |
2019-05-08 |
| Confo Therapeutics–SEVERAL: investment, 201905 financing round Series A €30m led by BGV + co-led by Wellington Partners |
2019-05-07 |
| Confo Therapeutics–Wellington Partners: investment, 201905 financing round Series A totalling €30m incl new + co-lead investor Wellington Partners |
2019-05-07 |
| DyNAbind–High-Tech Gründerfonds: investment, 201905 seed financing round incl new investor HTGF |
2019-05-07 |
| DyNAbind–Saxony (govt): investment, 201905 seed financing round incl new investor Technologiegründerfonds Sachsen |
2019-05-07 |
| DyNAbind–SEVERAL: investment, 201905 seed financing round from HTGF + TGFS + TUDAG |
2019-05-07 |
| DyNAbind–TU Dresden: investment, 201905 seed financing round incl existing investor TUDAG TU Dresden AG |
2019-05-07 |
| Merck (DE)–DyNAbind: drug discovery technology, 201905 collab existent marketing of DEL discovery kit with Merck KGaA |
2019-05-07 |
| Northwestern Univ–DyNAbind: drug discovery technology, 201905 collab existent with Northwestern Univ Chicago |
2019-05-07 |
| OMass–DyNAbind: drug discovery technology, 201905 collab existent with OMass Therapeutics |
2019-05-07 |
| Sosei–DyNAbind: drug discovery technology, 201905 collab existent with Sosei Heptares |
2019-05-07 |
| Cutech (IT)–Symrise: investment, 201905 acquisition of Cutech Srl by Symrise |
2019-05-06 |
| Intermolecular–Merck (DE): investment, 201905– acquisition of Intermolecular Inc by Merck for $62m in cash at $1.2/share |
2019-05-06 |
| Chemical Solutions Ltd–SGS: investment, 201905 acquisition of CSL by SGS |
2019-05-03 |
| Amal Therapeutics–Boehringer: cancer drugs, 201905– collab clinical research combi study of ATP128 + BI754091 in colorectal cancer |
2019-05-02 |
| CStone–Numab: antibody cancer drug, 201905– collab + license for tri-specific antibody ND021 in Greater China + KR + SG |
2019-05-02 |
| miRdetect–Bremen (govt): investment, 201905 seed financing round 7-digit € from HTGF + BBM Bremen + a private investor |
2019-05-02 |
| miRdetect–High-Tech Gründerfonds: investment, 201905 seed financing round 7-digit € from HTGF + BBM Bremen + a private investor |
2019-05-02 |
| miRdetect–OTHER: investment, 201905 seed financing round 7-digit € from HTGF + BBM Bremen + a private investor |
2019-05-02 |
| miRdetect–SEVERAL: investment, 201905 seed financing round 7-digit € from HTGF + BBM Bremen + a private investor |
2019-05-02 |
| Alentis Therapeutics–Bellevue: investment, 201904 financing round Series A totalling CHF12.5m incl co-lead investor BB Pureos Bioventures |
2019-04-30 |
| Alentis Therapeutics–BioMedPartners: investment, 201904 financing round Series A totalling CHF12.5m incl co-lead investor BioMedPartners |
2019-04-30 |
| Alentis Therapeutics–France (govt): investment, 201904 financing round Series A totalling CHF12.5m incl co-investor Bpifrance |
2019-04-30 |
| Alentis Therapeutics–High-Tech Gründerfonds: investment, 201904 financing round Series A totalling CHF12.5m incl co-investor HTGF |
2019-04-30 |
| Alentis Therapeutics–Instinctif Partners: public relations, 201904 service existent media relations by Instinctif |
2019-04-30 |
| Alentis Therapeutics–Schroders: investment, 201904 financing round Series A totalling CHF12.5m incl co-investor Schroder Adveq |
2019-04-30 |
| Alentis Therapeutics–SEVERAL: investment, 201904 financing round Series A CHF12.5m co-led by BioMedPartners + BB Pureos Bioventures |
2019-04-30 |
| SGS–Veeva Systems: clinical research software, 201904– supply global implementation of Veeva Vault CTMS by SGS |
2019-04-30 |
| Vividion Therapeutics–Nextech: investment, 201904 financing round Series B totalling $82m incl new + lead investor Nextech Invest |
2019-04-30 |
| Vividion Therapeutics–SEVERAL: investment, 201904 financing round Series B $82m led by new investor Nextech Invest |
2019-04-30 |
| Canopy Biosciences–Ampersand: investment, 201904 strategic growth investment from Ampersand Capital Partners |
2019-04-29 |
| Zellkraftwerk–Canopy Biosciences: investment, 201904 acquisition of Zellkraftwerk GmbH by Canopy Biosciences |
2019-04-29 |
| ADC Therapeutics–Adagene: antibody technology, 201904– collab + license agreem €na using SAFEbody technology for ADC development |
2019-04-24 |
| Chiome Bioscience–Velabs Therapeutics: antibody drug discovery, 201904– collab using Velabs’ microfluidcs techn for functional antibody screening |
2019-04-24 |
| InfanDx–Arnika Beteiligungen: investment, 201904 financing round totalling up to €5.3m incl existing + co-investor Arnika Beteiligungen GmbH |
2019-04-24 |
| InfanDx–Bamed MAM Group: investment, 201904 financing round totalling up to €5.3m incl new investor Bamed MAM Group |
2019-04-24 |
| InfanDx–CVG Capital: investment, 201904 financing round totalling up to €5.3m incl new investor CVG Capital GmbH |
2019-04-24 |
| InfanDx–Life Science Inkubator: investment, 201904 financing round totalling up to €5.3m incl existing + co-investor LSI-Pre-Seed-Fonds GmbH |
2019-04-24 |
| InfanDx–SEVERAL: investment, 201904 financing round up to €5.3m milestone-based from Bamed MAM + CVG Capital + LSI PreSeed + Arnika Beteiligungen |
2019-04-24 |
| Poseida Therapeutics–Novartis: investment, 201904 financing round Series C totalling $142m incl $75m from lead investor Novartis Pharma AG |
2019-04-22 |
| Poseida Therapeutics–SEVERAL: investment, 201904 financing round Series C $142m led by Novartis with $75m |
2019-04-22 |
| Arrakis Therapeutics–HBM: investment, 201904 financing round Series B totalling $75m incl new + co- investor HBM Healthcare Investments |
2019-04-18 |
| Arrakis Therapeutics–Nextech: investment, 201904 financing round Series B totalling $75m incl co-lead investor Nextech Invest |
2019-04-18 |
| Arrakis Therapeutics–SEVERAL: investment, 201904 financing round Series B $75m co-led by VenBio Partners + Nextech Invest |
2019-04-18 |
| Boehringer–PureTech Health: cancer immunotherapy, 201904– colllab research up to $226m + royalties using lymphatic targeting platform for I-O drugs |
2019-04-17 |
| Hookipa–Bank of America: financial services, 201904 supply service BofA Merrill Lynch is joint book-running manager for IPO |
2019-04-17 |
| Hookipa–RBC Capital Markets: financial services, 201904 supply service RBC Capital Markets is joint book-running manager for IPO |
2019-04-17 |
| Hookipa–SVB: financial services, 201904 supply service SVP Leerink is joint book-running manager for IPO |
2019-04-17 |
| Hookipa–Van Lanschot: financial services, 201904 supply service Kempen is co-manager for IPO |
2019-04-17 |
| Bruker–Univ Nijmegen: mass spectrometry, 201904– collab establishment of joint Center of Excellence for Translational Omics at RUMC TML |
2019-04-16 |
| Cevec–SEVERAL: investment, 201904 financing round Series D from new + existing investors |
2019-04-16 |
| DNDi–Atomwise: AI-based drug discovery, 201904 collab existent €0 screening + discovery of potential drugs for Chagas disease at no cost for DNDi |
2019-04-16 |
| Univ Nijmegen–Bruker: mass spectrometer, 201904 supply existent several Bruker MS systems at RUMC TML |
2019-04-16 |
| Univ Nijmegen–Bruker: mass spectrometer, 201904c supply acquisition of timsTOF Pro IM-MS system by RUMC TML |
2019-04-16 |
| ETH Zürich–Agilent: mass spectrometer, 201904 supply new 6546 LC/Q-TOF MS system to lab of Nicola Zamboni |
2019-04-15 |
| Gilead–Novo Group: drug development, 201904– collab clinical research for NASH combining semaglutide + cilofexor + firsocostat Novo Nordisk |
2019-04-12 |
| Evotec–Indivumed: cancer drug discovery, 201904– collab strategic precision medicine for new colorectal cancer drugs |
2019-04-11 |
| BioAnalytix–Zukunftsfonds Heilbronn: investment, 201904 merger acquisition of BioAnalytix Inc by Protagen Protein Services GmbH |
2019-04-10 |
| DKSH–Bruker: analytical instruments, 201904– distribution excl extension for Bruker AXS products by DKSH in China |
2019-04-09 |
| Probiodrug–SEVERAL: investment, 201904 private placement €8.2m net €7.65m with 4.1m new shares at €2m led by Claus Christiansen et al. |
2019-04-09 |
| Phenex–Helmholtz: drug research, 201904– collab joint research in NASH + liver cancer metabolism with Heikenwälder Group at DKFZ |
2019-04-05 |
| AgomAb Therapeutics–Advent France Biotechnology: investment, 201904 financing round Series A totalling €21m incl co-lead investor Advent France |
2019-04-03 |
| AgomAb Therapeutics–Boehringer: investment, 201904 financing round Series A totalling €21m incl co-investor BIVF |
2019-04-03 |
| AgomAb Therapeutics–Omnes Capital: investment, 201904 financing round Series A totalling €21m incl co-investor Omnes |
2019-04-03 |
| AgomAb Therapeutics–Pontifax: investment, 201904 financing round Series A totalling €21m incl co-investor Pontifax |
2019-04-03 |
| AgomAb Therapeutics–SEVERAL: investment, 201904 financing round Series A €21m co-led by V-Bio Ventures + Advent France Biotechnology |
2019-04-03 |
| AgomAb Therapeutics–V-Bio Ventures: investment, 201904 financing round Series A totalling €21m incl co-lead investor V-Bio Ventures |
2019-04-03 |
| Bayer–Editas Medicine: genome editing + cell therapy, 201904– strategic research collab + cross-license CRISPR + iPSC technologies BlueRock Tx |
2019-04-03 |
| Dyne Therapeutics–Atlas Venture: investment, 201904 financing round Series A totalling $50m incl founding investor Atlas Venture |
2019-04-03 |
| Dyne Therapeutics–Forbion: investment, 201904 financing round Series A totalling $50m incl co-investor Forbion |
2019-04-03 |
| Dyne Therapeutics–MPM Capital: investment, 201904 financing round Series A totalling $50m incl co-investor MPM Capital |
2019-04-03 |
| Dyne Therapeutics–SEVERAL: investment, 201904 financing round Series A $50m from founding investor Atlas Venture plus Forbion + MPM Capital |
2019-04-03 |
| LabCorp–Qiagen: molecular companion diagnostics, 201904– collab LabCorp joins Qiagen’s Day-One Lab Readiness program |
2019-04-03 |
| Rave LLC–Bruker: investment, 201904 acquisition €na by Bruker |
2019-04-03 |
| Chr. Hansen–Lonza: microbiomic treatment, 201904– collab establishment 50/50 joint venture for developing + manufacturing microbiome treatments |
2019-04-02 |
| Immunic–Rx Communications: public relations, 201904 service existent by Rx Communications Group |
2019-04-02 |
| Khloris Biosciences–Bayer: investment, 201904 seed financing €na from Leaps by Bayer |
2019-04-02 |
| IFM Therapeutics–Novartis: investment, 201904– acquisition 100% of IMF Tre for $1.6b incl upfront payment + milestones ANNOUNCED |
2019-04-01 |
| Bayer–ProteoNic: rec protein production technology, 201903– license non-excl €na to use 2G UNic technology to boost rec protein production |
2019-03-28 |
| Polyneuron–New Enterprise Associates: investment, 201903 financing round Series A totalling CHF22.5m incl new + co-lead investor NEA |
2019-03-28 |
| Polyneuron–SEVERAL: investment, 201903 financing round Series A CHF22.5m led by Sofinnova Partners + incl NEA |
2019-03-28 |
| Polyneuron–Sofinnova: investment, 201903 financing round Series A totalling CHF22.5m incl new + lead investor Sofinnova Partners |
2019-03-28 |
| Breath Therapeutics–Canale Communications: public relations, 201903 service existent for US by Canale Communciations Inc |
2019-03-26 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 10 11 12 ... 30 31 32 
Date
![Picture [iito] No Content Marketing 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-no-content-marketing.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
